zmanindc, In Europe the commercial life of Vascepa is 10-11 years without
generics. The best thing we as shareholders should want is for AMRN to
select the right BP for a BO. The approval for Europe could begin as
early as late June or as late as November. BP will need to have time
to stock product for the launch and train sales reps...then there is
negotiations with individual countries over pricing. For this to be
done right it should be done by the new owner of AMRN. (Just look
how JT did with his partnership in the US for Vascepa.) Partners
don't care ... owners do. A sale of AMRN to BP primarily for Europe
is the best way to go.
Once a deal is done let the BP decide how they want to continue the
generic litigation. BP have strong political ties, financial resources,
and human resources to properly proceed. If they win they continue
to market Vascepa, if they lose they simply shift resources to sell
Vascepa to other parts of the globe. If any BP were watching the
court case because they were interested in acquiring Vascepa they
can still do so at a discount. Any major delays in a BO will make
AMRN less valuable as the commercial life of Vascepa is limited.
Just getting rid of JT through a buyout will be a blessing.
The man is poison.
Market Data 
Markets 
AI
